ALLMedicine™ Cardiovascular Risk Reduction Center

Jan 12th, 2021 - Background Evidence-based therapies are generally underused for cardiovascular risk reduction; however, less is known about contemporary patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Methods and Results Pharmac...

Dec 28th, 2020 - Triglycerides as target of cardiovascular risk reduction.|2020|Tietge UJF,|

Dec 5th, 2020 - Statins are highly effective therapies for reducing low-density lipoprotein cholesterol and preventing cardiovascular events. However, many patients taking statins experience statin-associated muscle symptoms. In the current manuscript, we review ...

Nov 20th, 2020 - EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.|2020|Aroda VR,Sabatine MS,|

Oct 30th, 2020 - Canagliflozin reduces cardiovascular events including hospitalization for heart failure (HHF) in patients with type 2 diabetes and cardiovascular risk. Elevated amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are associate...

Aug 10th, 2020 - 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.|2020|Das SR,Everett BM,Birtcher KK,Brown...

Mar 16th, 2019 - Although there has been substantial improvement in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and mortality globally (S1- 1–S1-3). In the United States, it is also the le...

Feb 1st, 2019 - Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large sta...

Jan 21st, 2019 - Question: What is the association of aspirin use with cardiovascular events and bleeding events in individuals without cardiovascular disease? Findings: In this meta-analysis of 13 trials with 164 225 participants without cardiovascular disease, a...

Jan 5th, 2019 - After the holidays, often as part of a New Year’s resolution, it is common for people to think about changing to a healthier diet. One option is the Mediterranean diet, which was recently named by U.S. News & World Report as the top overall diet, ...

Jan 12th, 2021 - Background Evidence-based therapies are generally underused for cardiovascular risk reduction; however, less is known about contemporary patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Methods and Results Pharmac...

Dec 28th, 2020 - Triglycerides as target of cardiovascular risk reduction.|2020|Tietge UJF,|

Dec 5th, 2020 - Statins are highly effective therapies for reducing low-density lipoprotein cholesterol and preventing cardiovascular events. However, many patients taking statins experience statin-associated muscle symptoms. In the current manuscript, we review ...

Nov 20th, 2020 - EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.|2020|Aroda VR,Sabatine MS,|

Oct 30th, 2020 - Canagliflozin reduces cardiovascular events including hospitalization for heart failure (HHF) in patients with type 2 diabetes and cardiovascular risk. Elevated amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are associate...

Oct 11th, 2020 - Multiple clinical trials demonstrate the efficacy of sodium-glucose co-transporter-2 (SGLT-2) inhibitors to reduce cardiovascular events in persons with diabetes.[1,2,3,4] Use of these agents has been associated with consistent reductions in the c...

Feb 27th, 2020 - This transcript has been edited for clarity. Today I'm going to continue my overview of the 2020 American Diabetes Association (ADA) Standards of Medical Care in Diabetes. Pharmacologic approaches to the management of glycemia in patients with typ...

Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascula...

Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascula...

Dec 13th, 2019 - Icosapent ethyl (Vascepa) has gained an indication from the Food and Drug Administration for reduction of cardiovascular events in patients with high triglycerides who are at high risk for cardiovascular events. Olivier Le Moal/Getty Images It is.